These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26842429)

  • 1. A practical divergence measure for survival distributions that can be estimated from Kaplan-Meier curves.
    Cox TF; Czanner G
    Stat Med; 2016 Jun; 35(14):2406-21. PubMed ID: 26842429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.
    Péron J; Roy P; Ozenne B; Roche L; Buyse M
    JAMA Oncol; 2016 Jul; 2(7):901-5. PubMed ID: 27124210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of exposure distribution adjusting for association between exposure level and detection limit.
    Yang Y; Shelton BJ; Tucker TT; Li L; Kryscio R; Chen L
    Stat Med; 2017 Aug; 36(18):2935-2946. PubMed ID: 28513091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A group sequential test for survival trials: an alternative to rank-based procedures.
    Li Z
    Biometrics; 1999 Mar; 55(1):277-83. PubMed ID: 11318168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves.
    Uno H; Tian L; Claggett B; Wei LJ
    Stat Med; 2015 Dec; 34(28):3680-95. PubMed ID: 26194988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of gastric cancer survival: using an artificial hierarchical neural network.
    Amiri Z; Mohammad K; Mahmoudi M; Zeraati H; Fotouhi A
    Pak J Biol Sci; 2008 Apr; 11(8):1076-84. PubMed ID: 18819544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of survival distributions in clinical trials: A practical guidance.
    Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
    Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.
    Díaz I; Colantuoni E; Hanley DF; Rosenblum M
    Lifetime Data Anal; 2019 Jul; 25(3):439-468. PubMed ID: 29492746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
    Huang B; Kuan PF
    Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of a decreasing hazard of patients with acute coronary syndrome.
    van Geloven N; Martin I; Damman P; de Winter RJ; Tijssen JG; Lopuhaä HP
    Stat Med; 2013 Mar; 32(7):1223-38. PubMed ID: 22829475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression models for the restricted residual mean life for right-censored and left-truncated data.
    Cortese G; Holmboe SA; Scheike TH
    Stat Med; 2017 May; 36(11):1803-1822. PubMed ID: 28106926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ball divergence for the equality test of crossing survival curves.
    You N; He X; Dai H; Wang X
    Stat Med; 2023 Dec; 42(29):5353-5368. PubMed ID: 37752757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Median tests for censored survival data; a contingency table approach.
    Tang S; Jeong JH
    Biometrics; 2012 Sep; 68(3):983-9. PubMed ID: 23189327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing therapeutic cancer vaccine trials with delayed treatment effect.
    Xu Z; Zhen B; Park Y; Zhu B
    Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of methods for estimating the attributable risk in the context of survival analysis.
    Gassama M; Bénichou J; Dartois L; Thiébaut AC
    BMC Med Res Methodol; 2017 Jan; 17(1):10. PubMed ID: 28114895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating efficacy in trials with selective crossover.
    Brentnall AR; Sasieni P; Cuzick J
    Stat Med; 2017 Jul; 36(15):2333-2346. PubMed ID: 28295486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications.
    Thorén FB; Anderson H; Strannegård Ö
    Cancer Immunol Immunother; 2013 Oct; 62(10):1547-51. PubMed ID: 23979447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.